Acquisitions

Organon-Dermavant Johnson & Johnson Merck KGaA Sanofi-Dren Bio Agreement AstraZeneca Merck Eli Lilly and Verve Therapeutics Sanofi

9 ARTICLES

3w ago

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.

9 ARTICLES

last mo.

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

5 ARTICLES

2mo ago

AstraZeneca Acquires Fusion Pharmaceuticals in $2.4 Billion Deal to Boost Cancer Treatment Pipeline

Acquisitions

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Merck Announces €3 Billion Acquisition of Springworks Therapeutics

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

SpringWorks Shares Surge on Reported Acquisition Talks with Merck KGaA

Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

Organon Acquires Dermavant from Roivant for Up to $1.2 Billion

AstraZeneca Acquires Fusion Pharmaceuticals in $2.4 Billion Deal to Boost Cancer Treatment Pipeline